RCT: Sintilimab vs. placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic esophageal squamous cell carcinoma.

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial – The BMJ

Commentary on Twitter

Compared with placebo, sintilimab in combination with chemo showed significant benefits in overall survival and progression free survival as first line treatment in patients with advanced or metastatic oesophageal squamous cell carcinoma, finds study https://t.co/m8Gn3SBmCu

— The BMJ (@bmj_latest) April 19, 2022